Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

National Longitudinal Cohort of Hematological Diseases

National Longitudinal Cohort of Hematological Diseases (NICHE)

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood diseases, the treatment methods, prognosis and medical expenses of these patients in China. Method The study will include patients diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders, autoimmune hemolytic anemia, large granular lymphocyte leukemia, essential thrombocythemia, blood infection or received bone marrow transplantation in the investigating hospitals from January 1, 2020, and collect basic information, diagnostic and treatment information, prognosis information, as well as medical expense information from medical records. In its current form, the NICHE registry incorporates historical data (collected from 2000) and is systematically collecting prospective data in two phases with broadening reach, and prospectively follow-up to collect the prognosis information.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020. Who Should NOT Join This Trial: - Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. - Alcohol and drug addictions affect their ability to comply with study requirements. - According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients who were diagnosed with acute myeloid leukemia, multiple myeloma, hemophilia, aplastic anemia, leukemia, myelodysplastic syndrome, lymphoma, bleeding disorders or received bone marrow transplantation in the investigating hospitals from January 1, 2020. Exclusion Criteria: * Long-term follow-up information for patients is not available for any reason, such as not being available or having a serious concomitant disease. * Alcohol and drug addictions affect their ability to comply with study requirements. * According to the investigator, there are conditions that may endanger the patient's safety or affect his/her compliance.

Locations (1)

Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, China